Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two RNAi-Related Patent Applications: Jan 10, 2008

Premium
Title: Methods for Expression of Small Antiviral RNA Molecules Within a Cell
 
Number: 20080003658
 
Filed: March 21, 2007
 
Lead Inventor: Xiao-Feng Qin, California Institute of Technology
 
The patent application, its abstract states, claims “methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double-stranded RNA complexes. Small interfering RNA can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that,” it adds.
 
The application also describes “methods for treating patients … suffering from infection, particularly infection with HIV,” the abstract states. “In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.”
 

 
Title: Methods for Expression of Small Antiviral RNA Molecules With Reduced Cytotoxicity Within a Cell
 
Number: 20080003682 
 
Filed: March 8, 2007
 
Lead Inventor: Carlos Lois-Caballe, California Institute of Technology
 
According to the patent application’s abstract, the invention comprises “methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. Small interfering RNA can be expressed using the methods of the invention within a cell.”
 
The abstract adds that the invention also comprises “methods for producing [a] siRNA-encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In … a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell,” it adds. “The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.